National Clinical Practice Guidelines for the management of non-small cell lung cancer in early, locally advanced and metastatic stages

被引：32

作者：

Barron-Barron, Feliciano ^{[1
]}

Guzman-De Aba, Enrique ^{[2
]}

Alatorre-Alexander, Jorge ^{[2
]}

Aldaco-Sarvide, Fernando ^{[3
]}

Bautista-Aragon, Yolanda ^{[4
]}

Blake-Cerda, Monica ^{[5
]}

Carolina Blanco-Vazquez, Yazmin ^{[5
]}

Campos-Gomes, Saul ^{[6
]}

Francisco Corona-Cruz, Jose ^{[1
]}

Antonio Iniguez-Garcia, Marco ^{[2
]}

Javier Lozano-Ruiz, Francisco ^{[7
]}

Maldonado-Magos, Federico ^{[1
]}

de la Mata-Moya, Dolores ^{[5
]}

Manuel Martinez-Barrera, Luis ^{[2
]}

Ramos-Prudencio, Rubi ^{[8
]}

Rodriguez-Cid, Jeronimo ^{[2
]}

Rivera-Rivera, Samuel ^{[4
]}

Rogelio Treth-Rosales, Raul ^{[4
]}

Rodrigo Aguilar-Ortiz, Marco ^{[6
,9
]}

Astudillo-de la Vega, Horacio ^{[4
]}

Javier Barajas-Figueroa, Luis ^{[10
]}

Barroso-Quiroga, Nimbe ^{[11
]}

Blanco-Salazar, Andres ^{[6
]}

Castillo-Ortega, Graciano ^{[12
]}

Manuel Dominguez-Parra, Luis ^{[13
]}

Isabel Enriquez-Aceves, Maria ^{[12
]}

Femandez-Orozco, Armando ^{[4
]}

Antonio Figueroa-Morales, Marco ^{[14
]}

Green-Schneewiss, Leon ^{[5
]}

Alejandro Gonzalez-Garay, Jorge ^{[9
]}

Gonzalez Ramirez-Benfield, Rogelio ^{[15
]}

Guadarrama-Orozco, Alberto ^{[4
]}

Guerrero-Ixtlahuac, Jorge ^{[1
]}

Hernandez-Barajas, David ^{[16
]}

Hernandez-Montes de Oca, Raymundo ^{[5
]}

Kelly-Garcia, Javier ^{[17
]}

Lazaro-Leon, Miguel ^{[18
]}

Silva-Bravo, Fernando ^{[19
]}

Luis Tellez-Becerra, Jose ^{[2
]}

Omar Macedo-Perez, Eleazar ^{[1
]}

Maza-Ramos, Gbert ^{[6
,9
]}

Luis Mayorga-Butron, Jose ^{[20
,21
]}

Beatriz Montano-Velazquez, Bertha ^{[20
]}

Murillo-Medina, Kartha ^{[22
]}

Narvaez-Fernandez, Salvador ^{[12
]}

Javier Ochoa-Carrillo, Francisco ^{[1
]}

Olivares-Beltran, Guillermo ^{[5
]}

Olivares-Torres, Carlos ^{[16
]}

Ponce de Leon-Castillo, Mario ^{[17
]}

Alberto Ponce-Viveros, Mario ^{[4
]}

机构：

[1] Inst Nacl Cancerol, Ciudad De Mexico, Mexico

[2] Inst Nacl Enfermedades Resp, Ciudad De Mexico, Mexico

[3] Inst Seguridad & Serv Sociales Bs Trabajadores Es, Ctr Med Nacl 20 Noviembre, Ciudad De Mexico, Mexico

[4] Inst Mexicano Seguro Social, Ctr Med Nacl Siglo 21, Hosp Oncol, Ciudad De Mexico, Mexico

[5] Ctr Med ABC, Ctr Canc ABC, Ciudad De Mexico, Mexico

[6] Inst Seguridad Social Estado Mexico & Municipios, Ctr Oncol Estatal, Toluca De Lerdo, Estado De Mexic, Mexico

[7] Ctr Oncol Med Sur, Ciudad De Mexico, Mexico

[8] SSA, Inst Nacl Ciencias Med & Nutr Dr Salvador Zubiran, Ciudad De Mexico, Mexico

[9] Guidelines Int Network North Amer, Steering Comitee, New York, NY USA

[10] Grp Angeles, Ciudad De Mexico, Mexico

[11] Hosp Univ Dr Angel Leano, Zapopan, Jalisco, Mexico

[12] Inst Mexicano Seguro Social, Guanajuato, Mexico

[13] Star Med, Tijuana, Baja California, Mexico

[14] Inst Mexicano Seguro Social, Ctr Med Noreste, UMA 25, Nuevo Leon, Mexico

[15] Hosp Civil Guadalajara, Guadalajara, Jalisco, Mexico

[16] Hosp Gen Estado, Hermosillo, Sonora, Mexico

[17] Inst Jaliciense Cancerol, Guadalajara, Jalisco, Mexico

[18] Hosp Gen Mexico Dr Eduardo Liceaga, Ciudad De Mexico, Mexico

[19] Inst Mexicano Seguro Social, Puebla, Mexico

[20] UNAM, Programa Maestria & Doctorado Ciencias Med, Fac Med, Unidad Posgrad, Ciudad De Mexico, Mexico

[21] Inst Nacl Pediat, Ciudad De Mexico, Mexico

[22] Inst Seguridad & Serv Sociales Trabajadores Estad, Hosp Reg Gen Zaragoza, Ciudad De Mexico, Mexico

来源：

SALUD PUBLICA DE MEXICO | 2019年 / 61卷 / 03期

关键词：

lung cancer; non-small cell lung cancer; early stage lung cancer; locally advanced lung cancer; metastatic lung cancer; practice guidelines; evidence based medicine; PHASE-III TRIAL; WHOLE-BRAIN RADIOTHERAPY; PLATINUM-BASED CHEMOTHERAPY; THERAPY ONCOLOGY GROUP; STEREOTACTIC ABLATIVE RADIOTHERAPY; PROPHYLACTIC CRANIAL IRRADIATION; ASSISTED THORACOSCOPIC SURGERY; PARTITIONING ANALYSIS RPA; INDIVIDUAL PATIENT DATA; GROWTH-FACTOR RECEPTOR;

D O I：

10.21149/9916

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Lung cancer is one the leading causes of mortality worldwide. Symptomatic manifestations of the disease generally occur in the advanced-stage setting, and therefore an important number of patients have advanced or metastatic disease by the time they are diagnosed. This situation contributes to a poor prognosis in the treatment of lung cancer. Evidence-based clinical recommendations are of great value to support decision-making for daily practice, and thus improving health care quality and patient outcomes. Objectives. This Clinical Practice Guideline (CPG) contains systematically-developed recommendations to support clinicians, patients and patientcarers, policy makers and other stakeholders in the diagnosis and management of patients with early, advanced and metastatic stages of non-small cell lung cancer. Materials and methods. This document was an initiative of the Mexican Society of Oncology (SMEO) in collaboration with Mexican Center of Clinical Excellence (Cenetec) according to International Standards. Such standards included those described by the IOM, NICE, SIGN and GI-N. An interdisciplinary Guideline Development Group (GDG) was put together which included medical oncologists, surgical oncologistsc, radiation therapists, and methodologists with expertise in critical appraisal, systematic reviews and clinical practice guidelines development. Results. 62 clinical questions were agreed among members of the GDG. With the evidence identified from systematic reviews, the GDG developed clinical recommendations using a Modified Delphi Panel technique. Patients' representatives validated them. Conclusions. These Clinical Practice Guideline aims to support the shared decision-making process for patients with different stages of non-small cell lung cancer. Our goal is to improve health-care quality on these patients.

引用

页码：359 / 414

页数：56

共 199 条

[1] Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04 [J].

Ahn, Jin Seok ;

Ahn, Yong Chan ;

Kim, Joo-Hang ;

Lee, Chang Geol ;

Cho, Eun Kyung ;

Lee, Kyu Chan ;

Chen, Ming ;

Kim, Dong-Wan ;

Kim, Hoon-Kyo ;

Min, Young Joo ;

Kang, Jin-Hyoung ;

Choi, Jin-Hyuck ;

Kim, Sang-We ;

Zhu, Guangying ;

Wu, Yi-Long ;

Kim, Sung Rok ;

Lee, Kyung Hee ;

Song, Hong Suk ;

Choi, Yoon-La ;

Sun, Jong-Mu ;

Jung, Sin-Ho ;

Ahn, Myung-Ju ;

Park, Keunchil .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (24) :2660-U124

[2] Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].

Albain, Kathy S. ;

Swann, R. Suzanne ;

Rusch, Valerie W. ;

Turrisi, Andrew T., III ;

Shepherd, Frances A. ;

Smith, Colum ;

Chen, Yuhchyau ;

Livingston, Robert B. ;

Feins, Richard H. ;

Gandara, David R. ;

Fry, Willard A. ;

Darling, Gail ;

Johnson, David H. ;

Green, Mark R. ;

Miller, Robert C. ;

Ley, Joanne ;

Sause, Willliam T. ;

Cox, James D. .

LANCET, 2009, 374 (9687) :379-386

[3]

Andre F, 2001, CANCER, V91, P2394, DOI 10.1002/1097-0142(20010615)91:12<2394::AID-CNCR1273>3.3.CO

[4]

2-Y

[5]

[Anonymous], 1992, GUIDELINES CLIN PRAC

[6]

[Anonymous], BMJ QUAL SAF

[7]

[Anonymous], CANC PULM MEX

[8]

[Anonymous], 2014, DECISION MAKING HLTH, DOI DOI 10.1017/CBO9781139506779

[9]

[Anonymous], 2011, BMJ, V343, pd5928, DOI [DOI 10.1136/BMJ.D5928, 10.1136/bmj.d5928]

[10]

[Anonymous], 2012, GUID MAN PROC METH

← 1 2 3 4 5 6 7 8 9 10 →